Natalizumab restores evoked potential abnormalities in patients with relapsing-remitting multiple sclerosis

Multiple Sclerosis Journal

Volumn 17, Issue 2, 2011, Pages 198-203

  Meuth, Sven G ^a,b   Bittner, Stefan ^a   Seiler, Carola ^a   Göbel, Kerstin ^b   Wiendl, Heinz ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

evoked potentials; MS; multiple sclerosis; natalizumab; neurophysiology

Indexed keywords

NATALIZUMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE DURATION; EVOKED MUSCLE RESPONSE; EVOKED RESPONSE; EVOKED SOMATOSENSORY RESPONSE; EVOKED VISUAL RESPONSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NERVE CONDUCTION; RECURRENT DISEASE; TREATMENT RESPONSE;

EID: 79951545287     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510386998     Document Type: Article

References (20)

1. Polman CH, O'Connor PW, Havrdova E., Hutchinson M., Kappos L., Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006 ; 354: 899-910.
2. Rudick RA, Stuart WH, Calabresi PA, Confavreux C., Galetta SL, Radue EW, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006 ; 354: 911-923.
3. Havrdova E., Galetta S., Hutchinson M., Stefoski D., Bates D., Polman CH, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009 ; 8: 254-260.
4. Balcer LJ, Baier ML, Cohen JA, Kooijmans MF, Sandrock AW, Nano-Schiavi ML, et al. Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite. Neurology 2003 ; 61: 1367-1373. (Pubitemid 37463372)
5. Balcer LJ, Galetta SL, Calabresi PA, Confavreux C., Giovannoni G., Havrdova E., et al. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology 2007 ; 68: 1299-1304. (Pubitemid 46625976)
6. Stone LA Getting the measure of multiple sclerosis. Lancet Neurol 2009 ; 8: 221-222.
7. Rudick RA, Polman CH, Cohen JA, Walton MK, Miller AE, Confavreux C., et al. Assessing disability progression with the Multiple Sclerosis Functional Composite. Mult Scler 2009 ; 15: 984-997.
8. Leocani L. and Comi G. Neurophysiological markers. Neurol Sci 2008 ; 29: S218-221.
9. Polman CH, Reingold SC, Edan G., Filippi M., Hartung HP, Kappos L., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the ''McDonald Criteria''. Ann Neurol 2005 ; 58: 840-846. (Pubitemid 41746873)
10. Kallmann BA, Fackelmann S., Toyka KV, Rieckmann P. and Reiners K. Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis. Mult Scler 2006 ; 12: 58-65. (Pubitemid 43169238)
11. Meyer BU, Britton TC, Benecke R., Bischoff C., Machetanz J. and Conrad B. Motor responses evoked by magnetic brain stimulation in psychogenic limb weakness: diagnostic value and limitations. J Neurol 1992 ; 239: 251-255.
12. Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983 ; 33: 1444-1452. (Pubitemid 14237132)
13. Amato MP and Portaccio E. Clinical outcome measures in multiple sclerosis. J Neurol Sci 2007 ; 259: 118-222.
14. Clifford DB, De Luca A., Simpson DM, Arendt G., Giovannoni G. and Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010 ; 9: 438-446.
15. White AT and Petajan JH Physiological measures of therapeutic response to interferon beta-1a treatment in remitting-relapsing MS. Clin Neurophysiol 2004 ; 115: 2364-2371. (Pubitemid 39200802)
16. Anlar O., Kisli M., Tombul T. and Ozbek H. Visual evoked potentials in multiple sclerosis before and after two years of interferon therapy. Int J Neurosci 2003 ; 113: 483-489. (Pubitemid 36538528)
17. Liscic RM and Brecelj J. Visual evoked potentials in multiple sclerosis patients treated with interferon beta-1a. Croat Med J 2004 ; 45: 323-327. (Pubitemid 38724612)
18. Fuhr P., Borggrefe-Chappuis A., Schindler C. and Kappos L. Visual and motor evoked potentials in the course of multiple sclerosis. Brain 2001 ; 124: 2162-2168. (Pubitemid 33055361)
19. Weinstock-Guttman B., Baier M., Stockton R., Weinstock A., Justinger T., Munschauer F., et al. Pattern reversal visual evoked potentials as a measure of visual pathway pathology in multiple sclerosis. Mult Scler 2003 ; 9: 529-534. (Pubitemid 37287736)
20. Jung P., Beyerle A. and Ziemann U. Multimodal evoked potentials measure and predict disability progression in early relapsing-remitting multiple sclerosis. Mult Scler 2008 ; 14: 553-556. (Pubitemid 351943871)